Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Glossary

The Paul-Ehrlich-Institut has developed the definitions in this glossary to help users understand regulatory and biomedical terminology. Definitions may differ from those given in German and European Union legislation and medicine. Many definitions correspond to the glossary entries on the pages of the European Medicines Agency (EMA).

Bioavailability

The extent to which an active ingredient is absorbed from a medicine and becomes available in the body.

Updated: 21.11.2019

Biomarker

A biological molecule found in blood, other body fluids, or tissues that can be used to follow up body processes and diseases in humans and animals.

Updated: 21.11.2019

Biomedicine

A biological medicinal product is a medicinal product whose active substance is of biological origin or derived from biological source material.

Updated: 21.11.2019

Biosimilar Medicine

A biosimilar medicine ("biosimilar") is a medicine which is very similar to another biological medicine already marketed in the EU (the so-called reference medicine).

Updated: 27.04.2023

Biotechnology

The use of living organisms to create or modify products, including medicines.

Updated: 21.11.2019

Black Triangle

Since 2013, medicines under additional surveillance are marked with a black triangle in all EU Member States. Additional monitoring is usually done because there is less information available to them than to other medicines. The reasons may be because the product is new to the market or because there is insufficient data on its long-term use. The black triangle indicates that this product is being monitored even more strictly than other medicines. It does not mean that the medicine is not safe.

Updated: 27.04.2023

BMG - Bundesministerium für Gesundheit

Federal Ministry of Health (Bundesministeriunm für Gesundheit, BMG): The Federal Ministry of Health is responsible for a variety of policy areas at its headquarters in Bonn and at its headquarters in Berlin. The work focuses on preparing draft laws, ordinances and administrative regulations.

Updated: 27.04.2023

BZgA - Bundeszentrale für gesundheitliche Aufklärung

Bundeszentrale für gesundheitliche Aufklärung, BZgA [Federal Centre for Health Education]): More health for the citizens is the goal to which the BZgA is committed. As a specialist authority for health promotion, it develops strategies for health education and prevention, together with cooperation partners, and implements them in campaigns and projects.

Updated: 27.04.2023